ConcertAI
Summary New Core Watchlist Market Weak signals Manual checks Gaps & log Sources
Executive summary
- TEMPLATE VERDICT: the 'neutral, partner-assembled clinical-depth + AI-SaaS' model is viable and PROFITABLE at ~$250M scale (ConcertAI exited FY2024 profitable) — a real, replicable alternative to owning a lab — but it is fragile on three axes: non-exclusive molecular partners, oncology-only concentration, and clinicogenomic depth (~500K) that is a fraction of headline RWD. ↳
- TOP INOVALON SIGNAL: ConcertAI's CEO since May 2025 is Eron Kelly — the former PRESIDENT of Inovalon (2021–2025) who led Inovalon's pure-play SaaS/DaaS transformation — so a direct competitor is now run by an Inovalon insider carrying its playbook and org knowledge. ↳
- Partner-assembled molecular model is REAL and independently corroborated from the lab side: Caris's 10-K and Guardant's SEC exhibit both name ConcertAI as a clinical-data partner — but the same Caris filing lists ConcertAI alongside Flatiron and COTA, proving the molecular data is NON-EXCLUSIVE (the model's core durability risk). ↳
- NEUTRALITY TENSION (decision-grade): ConcertAI sells itself as the 'no-Roche-conflict' alternative to Roche-owned Flatiron, yet its largest/newest clinicogenomic asset (Jan 2026, ~500K patients) is built on Roche-owned Foundation Medicine — the same molecular source Flatiron's CGDB uses. ↳
- NEUTRALITY traction is real but UNPROVEN as the deciding factor: Tempus's 10-K names ConcertAI a top-3 Data-and-Services competitor (with Flatiron and IQVIA) and ConcertAI claims 75% of top-30 pharma — but no evidence pharma picks it specifically to avoid Roche, the same limit as the Optum trust wedge. ↳
- PROFITABILITY is the standout contrast vs Tempus: ConcertAI reported FY2024 revenue of $248M (up from $160M), 72% recurring, and its first profitable year (mid-teens EBITDA) — evidence the asset-light partner+SaaS model avoids owned-lab capital intensity (all company-reported, unaudited). ↳
- ONCOLOGY-BOUND: the partner-assembled clinicogenomic RWD model has NOT extended to new therapeutic areas — the only non-oncology footprint is TeraRecon imaging (cardiac/structural-heart), a separate product line, not the RWD model generalizing. ↳
- ACT agentic-AI trials platform (launched SCOPE Feb 2026) is real but its headline metrics — 10–20 month timeline cuts, ~50% design-time/amendment reduction — are VENDOR CLAIMS repeated by trade press with no independent or customer benchmark; treat as unverified. ↳
New since last run
factnew Caris Life Sciences' FY2025 10-K names ConcertAI as a clinical-data partner — 'we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies' — independently confirming both the partner-assembled model and that ConcertAI's molecular partners treat it as interchangeable with Flatiron/COTA.
factnew On 12 Jan 2026 ConcertAI and Foundation Medicine announced integration of FMI's de-identified multimodal genomic data with ConcertAI's clinical data, yielding what ConcertAI calls the largest clinically-linked oncology dataset at 'nearly half a million patients' (multimodal: whole-slide imaging, gene expression, IHC, signatures like MTAP loss).
factnew Guardant Health's Q4-2024 earnings exhibit (filed with the SEC) states Guardant 'entered into a collaboration with ConcertAI to create a differentiated data-as-a-service platform that integrates comprehensive EMR records with both genomic and epigenomic tumor profiling data' — a second molecular partner (liquid biopsy + epigenomics) corroborated from the partner's own filing.
factnew ConcertAI signed a multi-year agreement with Bayer (Apr 2025) for precision oncology using its Translational360 platform — an integrated longitudinal clinical-molecular database powered by Guardant Health liquid-biopsy data and the CancerLinQ network (9M+ records, 50 states), offering both tissue and liquid biopsy molecular data.
factnew ConcertAI and NeoGenomics announced (Dec 2024) a joint AI-SaaS solution for hematology clinical research (protocol optimization/study design across major hematologic malignancies) — adding a molecular partner for heme, alongside tissue (Caris, Foundation Medicine), liquid biopsy (Guardant) and histopathology (PathAI).
inferencenew ConcertAI assembles clinicogenomic depth entirely through non-owned molecular partners (Guardant, Caris, Foundation Medicine, NeoGenomics, PathAI) while owning the clinical-data layer (CancerLinQ/Patient360) and the AI/integration layer (CARAai); this is the decisive structural contrast with Tempus's owned-sequencing-lab model and the most replicable template for a claims-first vendor adding clinical/molecular depth without owning a lab.
inferencenew The core durability risk of the partner-assembled model: ConcertAI's molecular data is NON-EXCLUSIVE — Caris's 10-K lists ConcertAI alongside Flatiron and COTA as interchangeable clinical-data partners, and ConcertAI's AbbVie win was a three-way deal where Caris (not ConcertAI) supplied the multimodal molecular data — so a molecular partner can serve ConcertAI's rivals and ConcertAI cannot lock the genomic supply the way an owned lab can.
inferencenew Neutrality contradiction worth exploiting/learning from: ConcertAI markets itself as the independent 'no Roche conflict' alternative to Roche-owned Flatiron, yet its largest and newest clinicogenomic asset (Jan 2026, ~500K patients) is built on Foundation Medicine — which is Roche-owned, the same molecular source underpinning Flatiron's CGDB — so its differentiation is independence of the CLINICAL layer, not of the molecular layer.
factnew Independent competitor recognition: Tempus AI's FY2024 10-K names ConcertAI as one of its 'main competitors' for Data and Services 'that help pharmaceutical and biotechnology companies acquire data,' explicitly grouped with Flatiron Health and IQVIA — ConcertAI is a recognized top-tier oncology RWD competitor per its closest rival's SEC filing.
inferencenew The neutrality wedge has real competitive traction but is unproven as the deciding purchase factor: ConcertAI is independently recognized as an independent alternative (Tempus's 10-K lists it vs Flatiron/IQVIA; Caris treats it as an independent partner) and claims 75% of top-30 life-sciences customers, but no source shows pharma selecting it specifically to avoid Roche/Flatiron rather than on data quality or price — the same 'positionable but unproven' limit seen with Optum's UHG-conflict wedge.
factnew CancerLinQ — formerly ASCO's real-world oncology platform — is now a ConcertAI initiative under a multi-year cooperation agreement with ASCO (ASCO Certified quality measures, ConcertAI Patient360 for ASCO/affiliated research, and CancerLinQ TrialLinQ for ASCO clinical studies); this is the data spine that gives ConcertAI a society-endorsed oncology network without owning the providers.
inferencenew ConcertAI's scale numbers are company-reported and vary by what they measure: a 13M-patient Patient360 datalake from ~1,000 cancer centers across 50 states; ~9M CancerLinQ records; but only ~500K MATCHED clinicogenomic patients after the Foundation Medicine integration — i.e. true molecular depth is a small fraction of headline RWD, comparable in magnitude to Flatiron's ~400K-sample CGDB.
factnew ConcertAI's Precision360 is marketed with weekly data curation ('refreshed weekly'), 120+ curated variables, longitudinal completeness, and validated mortality — the recency and mortality-validation claims the brief flagged are confirmed as company-stated (ConcertAI blog/factsheets), not independently audited.
factnew TeraRecon is a CURRENT ConcertAI asset (acquired 2020, integrated Nov 2021; NOT divested) operating an FDA-cleared medical-imaging AI line — 6 openFDA 510(k) clearances under 'Terarecon, Inc.', most recent 23 Oct 2025 (Cardiovascular.Calcification.CT), spanning cardiac/neuro/structural-heart; it is ConcertAI's main non-oncology footprint and surpassed 2,000 global imaging customers in Sep 2025.
factnew ConcertAI launched Accelerated Clinical Trials (ACT), an enterprise agentic-AI trials platform built on CARAai, at SCOPE (Orlando, 2–5 Feb 2026); it deploys AI agents for literature review, protocol design, feasibility, site selection and patient matching, and is positioned to compete with CRO/RWD trial tools (Truveta Live Link, Inovalon's eligibility-screening).
inferencenew ACT's headline performance metrics — shortening trial timelines by 10–20 months, cutting study-design time up to 50% and amendments by ~50%, and 25–50% recruitment/activation speedups — are vendor claims sourced to ConcertAI's own press release and repeated verbatim by trade outlets; with the product weeks old there is no independent or customer-validated benchmark, and SCOPE 2026 coverage shows many vendors making near-identical agentic-AI-for-trials claims.
factnew AI product portfolio (shipped, not just roadmap): CARAai is ConcertAI's multi-LLM agentic platform (presented at NVIDIA GTC 2025, built with an NVIDIA collaboration on oncology-trial AI agents); on top of it sit Translational360 (molecular DB, Apr 2025), ACT (trials, Feb 2026), the Cadence Suite (commercial-team insights, Apr 2026), and a CancerLinQ point-of-care AI trial-matching suite (May 2026).
factnew At JPM (Jan 2025) ConcertAI reported FY2024 revenue of $248M (up from ~$160M in FY2023, ~55% growth), 72% of revenue recurring (its highest ever), and its FIRST profitable year at mid-teens unadjusted EBITDA margin — higher revenue and clearer profitability than the brief's '~$200M / ~30% ARR growth' framing (all company-reported, unaudited, private company).
inferencenew ConcertAI's profitability is the sharpest evidence the asset-light model beats owned-lab economics: it reports positive EBITDA at ~$250M revenue while owned-lab peer Tempus AI runs large GAAP losses — supporting the thesis that a claims/clinical-data + partner-molecular + SaaS stack scales to profit without sequencing-lab capex (caveat: ConcertAI figures are self-reported and unaudited).
factnew Customer base (company-reported): ConcertAI claims ~75% of the top-30 life-sciences organizations and ~50 named life-science customers plus ~2,000 providers/medical societies; documented named wins include a three-way AbbVie/Caris deal (Jan 2024) and Bayer (Apr 2025). The brief's 'Labcorp Drug Development' win could not be independently confirmed this pass.
factnew Ownership/funding (partially verified): ConcertAI traces to SymphonyAI/Wadhwani lineage (legal entity Precision Health AI), has raised on the order of $300M including a ~$150M round, and last carried a ~$1.9B valuation in 2022 — no newer priced round surfaced this pass, so the valuation figure is stale and the current cap table is a coverage gap.
factnew ConcertAI named Eron Kelly CEO effective 1 May 2025 (founder Jeff Elton moved to Vice Chairman). Kelly joined directly from Inovalon, where he was PRESIDENT from 2021–2025 and led Inovalon's transformation into a pure-play cloud SaaS/DaaS provider; he was previously a Microsoft (Office 365) and AWS executive — a direct competitor is now run by a senior Inovalon insider.
inferencenew Inovalon-specific implication of the Kelly hire: ConcertAI's CEO carries Inovalon's pure-play SaaS/DaaS transformation playbook plus insider knowledge of Inovalon's data assets, org and pharma GTM into a competitor — expect ConcertAI to sharpen an enterprise-SaaS motion and to contest overlapping life-sciences buyers; Inovalon should assume its recent strategy is well understood by this rival.
factnew International footprint: ConcertAI is headquartered in Cambridge, MA with offices in Bangalore, Frankfurt, Tokyo, Philadelphia and Raleigh-Durham — consistent with serving global pharma and operating lower-cost data-curation/engineering (Bangalore) capacity.
inferencenew Concentration limit (decision-grade): ConcertAI's partner-assembled clinicogenomic RWD model is oncology/hematology-bound and has not generalized to other therapeutic areas — its only non-oncology footprint is the TeraRecon imaging line (cardiac/neuro/structural-heart), a separate acquired product, not the RWD/clinicogenomic engine extending into new diseases; therapeutic breadth is the model's clearest scaling ceiling vs claims-based players like Inovalon/IQVIA/Optum.
factnew Scientific-credibility signal: 24 peer-reviewed oncology RWE papers (Jan 2024–Jun 2026) carry ConcertAI affiliations, including real-world trial-emulation methodology (the ENCORE framework, Clinical Pharmacology & Therapeutics) and work first-authored by George W. Sledge Jr. — a marquee oncologist — indicating genuine methodological depth behind the marketing, not just data licensing.
factnew ConcertAI is pushing its oncology RWD spine into point-of-care provider workflow: in May 2026 it expanded the CancerLinQ Suite with AI-driven trial matching and contextualized patient insights for oncologists at the point of care — a move that deepens the ASCO/provider relationship and feeds prospective trial recruitment back into the data flywheel.
Core competitors
Watchlist headlines
ConcertAI
factnew Caris Life Sciences' FY2025 10-K names ConcertAI as a clinical-data partner — 'we have entered into agreements with clinical data partners, such as ConcertAI, Flatiron and COTA, to enable the creation of matched clinico-genomic datasets that can be licensed to biopharma companies' — independently confirming both the partner-assembled model and that ConcertAI's molecular partners treat it as interchangeable with Flatiron/COTA.
factnew On 12 Jan 2026 ConcertAI and Foundation Medicine announced integration of FMI's de-identified multimodal genomic data with ConcertAI's clinical data, yielding what ConcertAI calls the largest clinically-linked oncology dataset at 'nearly half a million patients' (multimodal: whole-slide imaging, gene expression, IHC, signatures like MTAP loss).
factnew Guardant Health's Q4-2024 earnings exhibit (filed with the SEC) states Guardant 'entered into a collaboration with ConcertAI to create a differentiated data-as-a-service platform that integrates comprehensive EMR records with both genomic and epigenomic tumor profiling data' — a second molecular partner (liquid biopsy + epigenomics) corroborated from the partner's own filing.
factnew ConcertAI signed a multi-year agreement with Bayer (Apr 2025) for precision oncology using its Translational360 platform — an integrated longitudinal clinical-molecular database powered by Guardant Health liquid-biopsy data and the CancerLinQ network (9M+ records, 50 states), offering both tissue and liquid biopsy molecular data.
factnew ConcertAI and NeoGenomics announced (Dec 2024) a joint AI-SaaS solution for hematology clinical research (protocol optimization/study design across major hematologic malignancies) — adding a molecular partner for heme, alongside tissue (Caris, Foundation Medicine), liquid biopsy (Guardant) and histopathology (PathAI).
inferencenew ConcertAI assembles clinicogenomic depth entirely through non-owned molecular partners (Guardant, Caris, Foundation Medicine, NeoGenomics, PathAI) while owning the clinical-data layer (CancerLinQ/Patient360) and the AI/integration layer (CARAai); this is the decisive structural contrast with Tempus's owned-sequencing-lab model and the most replicable template for a claims-first vendor adding clinical/molecular depth without owning a lab.
inferencenew The core durability risk of the partner-assembled model: ConcertAI's molecular data is NON-EXCLUSIVE — Caris's 10-K lists ConcertAI alongside Flatiron and COTA as interchangeable clinical-data partners, and ConcertAI's AbbVie win was a three-way deal where Caris (not ConcertAI) supplied the multimodal molecular data — so a molecular partner can serve ConcertAI's rivals and ConcertAI cannot lock the genomic supply the way an owned lab can.
inferencenew Neutrality contradiction worth exploiting/learning from: ConcertAI markets itself as the independent 'no Roche conflict' alternative to Roche-owned Flatiron, yet its largest and newest clinicogenomic asset (Jan 2026, ~500K patients) is built on Foundation Medicine — which is Roche-owned, the same molecular source underpinning Flatiron's CGDB — so its differentiation is independence of the CLINICAL layer, not of the molecular layer.
factnew Independent competitor recognition: Tempus AI's FY2024 10-K names ConcertAI as one of its 'main competitors' for Data and Services 'that help pharmaceutical and biotechnology companies acquire data,' explicitly grouped with Flatiron Health and IQVIA — ConcertAI is a recognized top-tier oncology RWD competitor per its closest rival's SEC filing.
inferencenew The neutrality wedge has real competitive traction but is unproven as the deciding purchase factor: ConcertAI is independently recognized as an independent alternative (Tempus's 10-K lists it vs Flatiron/IQVIA; Caris treats it as an independent partner) and claims 75% of top-30 life-sciences customers, but no source shows pharma selecting it specifically to avoid Roche/Flatiron rather than on data quality or price — the same 'positionable but unproven' limit seen with Optum's UHG-conflict wedge.
factnew CancerLinQ — formerly ASCO's real-world oncology platform — is now a ConcertAI initiative under a multi-year cooperation agreement with ASCO (ASCO Certified quality measures, ConcertAI Patient360 for ASCO/affiliated research, and CancerLinQ TrialLinQ for ASCO clinical studies); this is the data spine that gives ConcertAI a society-endorsed oncology network without owning the providers.
inferencenew ConcertAI's scale numbers are company-reported and vary by what they measure: a 13M-patient Patient360 datalake from ~1,000 cancer centers across 50 states; ~9M CancerLinQ records; but only ~500K MATCHED clinicogenomic patients after the Foundation Medicine integration — i.e. true molecular depth is a small fraction of headline RWD, comparable in magnitude to Flatiron's ~400K-sample CGDB.
factnew ConcertAI's Precision360 is marketed with weekly data curation ('refreshed weekly'), 120+ curated variables, longitudinal completeness, and validated mortality — the recency and mortality-validation claims the brief flagged are confirmed as company-stated (ConcertAI blog/factsheets), not independently audited.
factnew TeraRecon is a CURRENT ConcertAI asset (acquired 2020, integrated Nov 2021; NOT divested) operating an FDA-cleared medical-imaging AI line — 6 openFDA 510(k) clearances under 'Terarecon, Inc.', most recent 23 Oct 2025 (Cardiovascular.Calcification.CT), spanning cardiac/neuro/structural-heart; it is ConcertAI's main non-oncology footprint and surpassed 2,000 global imaging customers in Sep 2025.
factnew ConcertAI launched Accelerated Clinical Trials (ACT), an enterprise agentic-AI trials platform built on CARAai, at SCOPE (Orlando, 2–5 Feb 2026); it deploys AI agents for literature review, protocol design, feasibility, site selection and patient matching, and is positioned to compete with CRO/RWD trial tools (Truveta Live Link, Inovalon's eligibility-screening).
inferencenew ACT's headline performance metrics — shortening trial timelines by 10–20 months, cutting study-design time up to 50% and amendments by ~50%, and 25–50% recruitment/activation speedups — are vendor claims sourced to ConcertAI's own press release and repeated verbatim by trade outlets; with the product weeks old there is no independent or customer-validated benchmark, and SCOPE 2026 coverage shows many vendors making near-identical agentic-AI-for-trials claims.
factnew AI product portfolio (shipped, not just roadmap): CARAai is ConcertAI's multi-LLM agentic platform (presented at NVIDIA GTC 2025, built with an NVIDIA collaboration on oncology-trial AI agents); on top of it sit Translational360 (molecular DB, Apr 2025), ACT (trials, Feb 2026), the Cadence Suite (commercial-team insights, Apr 2026), and a CancerLinQ point-of-care AI trial-matching suite (May 2026).
factnew At JPM (Jan 2025) ConcertAI reported FY2024 revenue of $248M (up from ~$160M in FY2023, ~55% growth), 72% of revenue recurring (its highest ever), and its FIRST profitable year at mid-teens unadjusted EBITDA margin — higher revenue and clearer profitability than the brief's '~$200M / ~30% ARR growth' framing (all company-reported, unaudited, private company).
inferencenew ConcertAI's profitability is the sharpest evidence the asset-light model beats owned-lab economics: it reports positive EBITDA at ~$250M revenue while owned-lab peer Tempus AI runs large GAAP losses — supporting the thesis that a claims/clinical-data + partner-molecular + SaaS stack scales to profit without sequencing-lab capex (caveat: ConcertAI figures are self-reported and unaudited).
factnew Customer base (company-reported): ConcertAI claims ~75% of the top-30 life-sciences organizations and ~50 named life-science customers plus ~2,000 providers/medical societies; documented named wins include a three-way AbbVie/Caris deal (Jan 2024) and Bayer (Apr 2025). The brief's 'Labcorp Drug Development' win could not be independently confirmed this pass.
factnew Ownership/funding (partially verified): ConcertAI traces to SymphonyAI/Wadhwani lineage (legal entity Precision Health AI), has raised on the order of $300M including a ~$150M round, and last carried a ~$1.9B valuation in 2022 — no newer priced round surfaced this pass, so the valuation figure is stale and the current cap table is a coverage gap.
factnew ConcertAI named Eron Kelly CEO effective 1 May 2025 (founder Jeff Elton moved to Vice Chairman). Kelly joined directly from Inovalon, where he was PRESIDENT from 2021–2025 and led Inovalon's transformation into a pure-play cloud SaaS/DaaS provider; he was previously a Microsoft (Office 365) and AWS executive — a direct competitor is now run by a senior Inovalon insider.
inferencenew Inovalon-specific implication of the Kelly hire: ConcertAI's CEO carries Inovalon's pure-play SaaS/DaaS transformation playbook plus insider knowledge of Inovalon's data assets, org and pharma GTM into a competitor — expect ConcertAI to sharpen an enterprise-SaaS motion and to contest overlapping life-sciences buyers; Inovalon should assume its recent strategy is well understood by this rival.
factnew International footprint: ConcertAI is headquartered in Cambridge, MA with offices in Bangalore, Frankfurt, Tokyo, Philadelphia and Raleigh-Durham — consistent with serving global pharma and operating lower-cost data-curation/engineering (Bangalore) capacity.
inferencenew Concentration limit (decision-grade): ConcertAI's partner-assembled clinicogenomic RWD model is oncology/hematology-bound and has not generalized to other therapeutic areas — its only non-oncology footprint is the TeraRecon imaging line (cardiac/neuro/structural-heart), a separate acquired product, not the RWD/clinicogenomic engine extending into new diseases; therapeutic breadth is the model's clearest scaling ceiling vs claims-based players like Inovalon/IQVIA/Optum.
factnew Scientific-credibility signal: 24 peer-reviewed oncology RWE papers (Jan 2024–Jun 2026) carry ConcertAI affiliations, including real-world trial-emulation methodology (the ENCORE framework, Clinical Pharmacology & Therapeutics) and work first-authored by George W. Sledge Jr. — a marquee oncologist — indicating genuine methodological depth behind the marketing, not just data licensing.
factnew ConcertAI is pushing its oncology RWD spine into point-of-care provider workflow: in May 2026 it expanded the CancerLinQ Suite with AI-driven trial matching and contextualized patient insights for oncologists at the point of care — a move that deepens the ASCO/provider relationship and feeds prospective trial recruitment back into the data flywheel.
Market & demand signals
No demand-side findings this run.
Weak signals
Single-signal inferences — interpret with caution.
Manual checks
Read Kelly's recent LinkedIn posts and his ConcertAI hires since May 2025 — watch for ex-Inovalon talent following him and for messaging that mirrors Inovalon's SaaS/DaaS pure-play narrative. Highest-value human check this run. — https://www.linkedin.com/search/results/content/?keywords=Eron%20Kelly%20ConcertAI
Check KLAS Research and Gartner for any ConcertAI vs Flatiron vs IQVIA vs Tempus ranking in oncology real-world data / life-sciences analytics — paywalled; needed to independently corroborate the '75% of top-30 pharma' and data-quality claims. — https://klasresearch.com/
Pull current ownership, latest priced round and valuation (legal entity 'Precision Health AI'); the public web only shows a stale 2022 ~$1.9B mark and a ~$150M round. Confirm SymphonyAI's current stake and any 2024-2026 raise. — https://pitchbook.com/profiles/company/90684-46
The brief lists Labcorp Drug Development (now Fortrea) as a ConcertAI win; not confirmed this pass. Search ConcertAI/Fortrea press and Fortrea filings to confirm or drop. — https://www.concertai.com/news/
Sponsor search returned 0 under 'ConcertAI'. Re-check ClinicalTrials.gov for 'Concerto HealthAI', 'CancerLinQ', and 'TeraRecon' as collaborator, and check whether ACT-supported trials surface a ConcertAI tie — confirms whether it appears in trial records at all. — https://clinicaltrials.gov/search?term=ConcertAI
Coverage gaps & run log
Coverage gaps
| Company | Category | Reason |
|---|---|---|
| ConcertAI | trials | all 4 scripted attempt(s) empty/failed (cap 4 for core tier) |
| ConcertAI | regulatory | all 2 scripted attempt(s) empty/failed (cap 4 for core tier) |
| ConcertAI | trials | ClinicalTrials.gov sponsor/collaborator + asset-term searches returned 0 under 'ConcertAI' — it does not register as a named trial sponsor; ACT/Digital-Trial work flows through pharma/CRO sponsors. Re-check aliases (Concerto HealthAI, CancerLinQ, TrialLinQ) manually. |
| ConcertAI | financial | Revenue $248M / first-profitable-year / 72% recurring / 75%-of-top-30-pharma are ALL company-reported (JPM self-presentation); no audited financials (private). Independent corroboration (KLAS/Gartner/PitchBook) is paywalled — see manual checks. |
| ConcertAI | financial | Current cap table / latest valuation unverified: only a stale 2022 ~$1.9B mark and a ~$150M round surfaced; SymphonyAI's current stake and any 2024-2026 raise unconfirmed. |
| ConcertAI | product | ACT trial-acceleration metrics (10-20 months, ~50% design/amendment) and Precision360 'weekly refresh' are vendor claims with NO independent/customer benchmark (ACT is weeks old); trade coverage merely repeats the press release. |
| ConcertAI | financial | 'Labcorp Drug Development' (now Fortrea) named-customer claim from the brief could not be independently confirmed this pass. |
Query log
| Source | Query | Results | Status |
|---|---|---|---|
| clinicaltrials | ct sponsor=ConcertAI | 0 | ok |
| clinicaltrials | ct term=Patient360 | 0 | ok |
| clinicaltrials | ct term=RWD360 | 0 | ok |
| clinicaltrials | ct term=Precision360 | 0 | ok |
| openfda-510k | 510k applicant=ConcertAI | 0 | ok |
| openfda-pma | pma applicant=ConcertAI | 0 | ok |
| pubmed | pubmed ConcertAI | 5440 | ok |
| fetch_nih_reporter.py | reporter text=ConcertAI | 0 | error: {"source": "nih_reporter", "error": "HTTP 404"} |
| edgar-fts | edgar fts ConcertAI | 53 | ok |
| pages | pages ConcertAI | 1 | ok |
| websearch | ConcertAI Foundation Medicine clinicogenomic data partnership 2026 | 7 | ok |
| websearch | ConcertAI ACT Accelerated Clinical Trials agentic AI platform SCOPE 2026 launch | 8 | ok |
| websearch | ConcertAI Bayer partnership tissue liquid biopsy molecular real-world data | 9 | ok |
| websearch | ConcertAI 2024 revenue profitable ARR growth funding investors valuation | 8 | ok |
| websearch | ConcertAI Patient360 RWD360 CancerLinQ ASCO patients providers data scale mortality | 9 | ok |
| websearch | ConcertAI Jeff Elton CEO neutral independent oncology data alternative Flatiron pharma | 16 | ok |
| websearch | ConcertAI customers 75% top 30 life sciences AbbVie Labcorp Drug Development pharma | 9 | ok |
| websearch | ConcertAI Eron Kelly CEO appointment 2025 background Microsoft leadership transition | 9 | ok |
| websearch | ConcertAI TeraRecon imaging divested sold spun off status 2022 2023 2024 | 8 | ok |
| websearch | ConcertAI international offices Bangalore Frankfurt Tokyo expansion beyond oncology | 9 | ok |
| websearch | ConcertAI NVIDIA NeoGenomics partnership oncology AI agents clinicogenomic 2025 2026 | 10 | ok |
| webfetch | SEC EDGAR extract: Tempus 10-K FY2024 ConcertAI competitor mention | 1 | ok |
| webfetch | SEC EDGAR extract: Caris 10-K FY2025 ConcertAI clinical-data-partner mention | 1 | ok |
| webfetch | SEC EDGAR extract: Guardant Health Q4-2024 EX-99.1 ConcertAI collaboration | 1 | ok |
| pubmed | TIGHT requery: "ConcertAI"[Affiliation] OR "Concerto HealthAI"[Affiliation] | 24 | ok |
| openfda-510k | 510k applicant=TeraRecon (ConcertAI imaging asset) | 6 | ok |
Sources
ConcertAI
- https://www.sec.gov/Archives/edgar/data/2019410/000201941026000016/cai-20251231.htm
- https://www.businesswire.com/news/home/20260112346958/en/ConcertAI-and-Foundation-Medicine-Integrate-Genomic-and-Clinical-Data-to-Transform-Translational-Research-and-Efficient-Drug-Development
- https://www.foundationmedicine.com/press-release/concertai
- https://hitconsultant.net/2026/01/15/oncology-concertai-foundation-medicine-clinico-genomic-data-2026/
- https://www.sec.gov/Archives/edgar/data/1576280/000157628025000043/gh-12312024xexhibit991.htm
- https://www.businesswire.com/news/home/20250422551624/en/ConcertAI-Announces-Strategic-Agreement-with-Bayer-to-Accelerate-Clinical-Development-in-Precision-Oncology
- https://hitconsultant.net/2025/04/25/bayer-leverages-concertais-translational360-platform-for-ai-driven-oncology/
- https://www.businesswire.com/news/home/20241205002549/en/ConcertAI-and-NeoGenomics-Announce-New-AI-Software-as-a-Service-Solution-for-Hematology-Clinical-Research
- https://www.prnewswire.com/news-releases/pathai-and-concertai-partner-to-create-first-in-class-histopathology-and-clinical-real-world-data-solutions-301806445.html
- https://www.prnewswire.com/news-releases/concertai-and-caris-life-sciences-announce-strategic-agreement-with-abbvie-to-accelerate-oncology-pipeline-and-clinical-trials-302029940.html
- https://rxalmanac.com/articles/top-real-world-evidence-vendors/
- https://www.sec.gov/Archives/edgar/data/1717115/000095017025025603/tem-20241231.htm
- https://www.concertai.com/blog/2023/12/the-next-horizon-concertai-and-cancerlinq
- https://www.concertai.com/rwd360-asco-factsheet
- https://www.concertai.com/fact-sheet_patient360
- https://www.concertai.com/blog/concertai-at-asco-2026-precision360-weekly-curation-powers-new-possibility
- https://www.concertai.com/patient360
- https://www.businesswire.com/news/home/20250925356377/en/ConcertAIs-TeraRecon-Surpasses-2000-Global-Customers-Accelerating-Cloud-First-SaaS-Transformation-to-Further-Unlock-Productivity-for-Healthcare-Providers
- https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K250288
- https://www.businesswire.com/news/home/20260202475918/en/ConcertAI-Launches-Accelerated-Clinical-Trials-Leveraging-Agentic-AI-to-Radically-Shorten-Trial-Timelines
- https://www.techtarget.com/pharmalifesciences/news/366638536/ConcertAI-unveils-agentic-AI-tool-to-cut-trial-timelines-costs
- https://www.clinicalresearchnewsonline.com/news/2026/02/03/scope-2026--ai-in-clinical-research-poised-for-boom-times
- https://www.biospace.com/press-releases/concertai-presents-caraai-multi-llm-and-agentic-ai-for-clinical-development-and-insights-at-nvidia-gtc-2025
- https://www.drugdiscoverytrends.com/nvidia-and-concertai-team-up-to-build-ai-agents-that-collaborate-on-oncology-trials/
- https://www.businesswire.com/news/home/20260421012128/en/ConcertAI-Introduces-Cadence-Suite-Delivering-Industry-Leading-Visibility-and-Predictive-Insights-into-the-Patients-Journey-for-Commercial-Teams
- https://finance.yahoo.com/news/concertai-presents-43rd-annual-j-170000801.html
- https://ai-techpark.com/concertai-announced-first-year-of-profitability-and-unveils-ai-roadmap/
- https://www.mobihealthnews.com/news/concertai-scores-150m-valuation-skyrockets-nearly-2b
- https://getlatka.com/companies/concertai
- https://www.concertai.com/news/concertai-announces-leadership-transition-to-accelerate-ai-innovation-and-growth
- https://www.citybiz.co/article/689143/concertai-appoints-eron-kelly-as-ceo/
- https://www.fundz.net/executives/concertai-hired-a397
- https://www.concertai.com/concertai-press-kit
- https://www.concertai.com/news/concertai-introduces-terarecon-av-advancing-ai-powered-medical-imaging-with-new-structural-heart-and-saas-capabilities
- https://pubmed.ncbi.nlm.nih.gov/41577635/
- https://pubmed.ncbi.nlm.nih.gov/40102447/
- https://pubmed.ncbi.nlm.nih.gov/42240135/
- https://www.businesswire.com/news/home/20260528899007/en/ConcertAI-Expands-CancerLinQ-Suite-with-AI-Driven-Trial-Matching-and-Contextualized-Patient-Insights-to-Support-Oncologists-at-the-Point-of-Care